Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Effectiveness and Safety for Re-Treatment with Brentuximab-Vedotin in Patients with Relapsed/Refractory (R/R) CD30+ Malignancies: A Retrospective Medical Chart Review Study in Spain. the Believe Study. NCT:04998331

Ramon Garcia-Sanz, Anna Sureda Balari, Eva Domingo Domenech, Francisco Javier Capote Huelva, Antonio Gutierrez, Antonia Rodriguez Izquierdo, Marta Grande De Domingo, Lourdes Baeza

Blood (2024) 144 (Supplement 1): 2376.

https://doi.org/10.1182/blood-2024-193585

Published: 2024

Journal Articles

Long-Term Follow-up of a Prospective Phase II Trial of Extended Treatment with Rituximab in Patients with B-Cell Post-Transplant Lymphoproliferative Disease and Comparison with a Cohort of Patients Treated in Real Life. Analysis on Behalf of the Spanish Lymphoma Group (GELTAMO)

Eva Gonzalez-Barca, MD PhD, Maria Queralt Salas Gay, MD, Francisco Javier Capote Huelva, Jose Gomez Codina, Carlos Panizo, MD PhD, Antonio Salar, MD PhD, Eva Domingo Domenech, MD, Alicia Bailen, Josep-Maria Ribera, MD, Andres Lopez, Javier Briones, MD, Andres Muñoz, Maite Encuentra, Alberto Fernandez de Sevilla, MD PhD

Blood (2017) 130 (Supplement 1): 1545.

https://doi.org/10.1182/blood.V130.Suppl_1.1545.1545

Published: 2017

Journal Articles

Response-Adapted Treatment with Rituximab/Bendamustine/Mitoxantrone/Dexamethasone and Maintenance Therapy with Rituximab in Patients with Follicular Lymphoma in Relapse or Refractory to First-Line Treatment with Immunochemotherapy. RBMDGELTAMO08 Trial

Francisco Javier Peñalver Párraga, José Antonio Márquez Navarro, Soledad Durán Nieto, Pilar Giraldo Castellano, Carlos Montalbán Sanz, María José Ramírez Sánchez, Juan-Manuel Sancho Cia, María José Terol Castera, Francisco Javier Capote Huelva, Antonio Gutiérrez García, Blanca Sánchez González, Antonio Salar Silvestre, Miguel Canales Albendea, MD PhD, María Dolores Caballero Barrigón

Blood (2016) 128 (22): 1788.

https://doi.org/10.1182/blood.V128.22.1788.1788

Published: 2016

Journal Articles

Role Of PET/CT In The Management Of Burkitt Lymphoma

Estrella Carrillo, MD, Fatima De la Cruz, Víctor Marín, María Solé, Isabel Borrego, Eduardo Quiroga, Marina Manzanares, Francisco Javier Capote, María José Ramirez, Ildefonso Espigado, Ricardo Vázquez, Pérez-Simón Jose Antonio

Blood (2013) 122 (21): 4311.

https://doi.org/10.1182/blood.V122.21.4311.4311

Published: 2013

Journal Articles

Rituximab, Bendamustine, Mitoxantrone, Dexamethasone (R-BMD) in Patients with Follicular Lymphoma in Relapse or Refractory to First-Line Treatment with Immunochemotherapy. R-BMD Geltamo 08 Trial

Francisco Javier Peñalver, José Antonio Márquez, Soledad Durán, Pilar Giraldo, Carlos Montalban, María José Ramírez, Juan Manuel Sancho, María José Terol, MD, PhD, Francisco Javier Capote, Antonio Gutiérrez, Blanca Sánchez, Miguel Canales, María Dolores Caballero

Blood (2012) 120 (21): 1639.

https://doi.org/10.1182/blood.V120.21.1639.1639

Published: 2012

Journal Articles

Autologous Stem Cell Transplantation and Rituximab for Mantle Cell Lymphoma.

Blood (2005) 106 (11): 2092.

https://doi.org/10.1182/blood.V106.11.2092.2092

Published: 2005

Journal Articles

Rituximab Plus Dose Enhancement and Biweekly Administration of CHOP for Newly-Diagnosed Patients with Diffuse Large-B-Cell Lymphoma.

Francisco Javier, Capote, E. Ríos, M. Almagro, J.M. Durán-Cabral, J.N. Rodríguez, S. Durán-Nieto, J. Bergua, L. Martino, A. Romero, M.V. Martín-Reina, J.L. Gil

Blood (2005) 106 (11): 4726.

https://doi.org/10.1182/blood.V106.11.4726.4726

Published: 2005

NARROW

Effectiveness and Safety for Re-Treatment with Brentuximab-Vedotin in Patients with Relapsed/Refractory (R/R) CD30+ Malignancies: A Retrospective Medical Chart Review Study in Spain. the Believe Study. NCT:04998331

Long-Term Follow-up of a Prospective Phase II Trial of Extended Treatment with Rituximab in Patients with B-Cell Post-Transplant Lymphoproliferative Disease and Comparison with a Cohort of Patients Treated in Real Life. Analysis on Behalf of the Spanish Lymphoma Group (GELTAMO)

Response-Adapted Treatment with Rituximab/Bendamustine/Mitoxantrone/Dexamethasone and Maintenance Therapy with Rituximab in Patients with Follicular Lymphoma in Relapse or Refractory to First-Line Treatment with Immunochemotherapy. RBMDGELTAMO08 Trial

Role Of PET/CT In The Management Of Burkitt Lymphoma

Rituximab, Bendamustine, Mitoxantrone, Dexamethasone (R-BMD) in Patients with Follicular Lymphoma in Relapse or Refractory to First-Line Treatment with Immunochemotherapy. R-BMD Geltamo 08 Trial

Autologous Stem Cell Transplantation and Rituximab for Mantle Cell Lymphoma.

Rituximab Plus Dose Enhancement and Biweekly Administration of CHOP for Newly-Diagnosed Patients with Diffuse Large-B-Cell Lymphoma.

Email alerts

ASH Publications

American Society of Hematology

Effectiveness and Safety for Re-Treatment with Brentuximab-Vedotin in Patients with Relapsed/Refractory (R/R) CD30+ Malignancies: A Retrospective Medical Chart Review Study in Spain. the Believe Study. NCT:04998331

Long-Term Follow-up of a Prospective Phase II Trial of Extended Treatment with Rituximab in Patients with B-Cell Post-Transplant Lymphoproliferative Disease and Comparison with a Cohort of Patients Treated in Real Life. Analysis on Behalf of the Spanish Lymphoma Group (GELTAMO)

Response-Adapted Treatment with Rituximab/Bendamustine/Mitoxantrone/Dexamethasone and Maintenance Therapy with Rituximab in Patients with Follicular Lymphoma in Relapse or Refractory to First-Line Treatment with Immunochemotherapy. RBMDGELTAMO08 Trial

Role Of PET/CT In The Management Of Burkitt Lymphoma

Rituximab, Bendamustine, Mitoxantrone, Dexamethasone (R-BMD) in Patients with Follicular Lymphoma in Relapse or Refractory to First-Line Treatment with Immunochemotherapy. R-BMD Geltamo 08 Trial

Autologous Stem Cell Transplantation and Rituximab for Mantle Cell Lymphoma.

Rituximab Plus Dose Enhancement and Biweekly Administration of CHOP for Newly-Diagnosed Patients with Diffuse Large-B-Cell Lymphoma.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only